Skip to main content










Fred Eshelman is the founder of Eshelman Ventures LLC, an investment company primarily interested in private health-care companies. Previously he founded and served as CEO and executive chairman of Pharmaceutical Product Development (PPDI, NASDAQ) prior to the sale of the company to private equity interests.

After PPD he served as the founding chairman and largest shareholder of Furiex Pharmaceuticals (FURX, NASDAQ), a company which licensed and rapidly developed new medicines. Furiex was sold to Forest Labs/Actavis in July, 2014.

His career has also included positions as senior vice president (development) and board member of the former Glaxo, Inc., as well as various management positions with Beecham Laboratories and Boehringer Mannheim Pharmaceuticals.

Eshelman has served on the executive committee of the Medical Foundation of North Carolina, was on the board of trustees for UNC-W and in 2011 was appointed by the NC General Assembly to serve on the Board of Governors for the state’s multicampus university system as well as the NC Biotechnology Center. In addition, he chairs the board of visitors for the UNC Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, one of the top pharmacy programs in the United States. In May 2008 the School was named for Eshelman in recognition of his many contributions to the school and the profession.

Eshelman has received many awards including the Davie and Distinguished Service Awards from UNC and Outstanding Alumnus from both the UNC and University of Cincinnati schools of pharmacy, as well as the N.C. Entrepreneur Hall of Fame Award. He earned a B.S. in pharmacy from the University of North Carolina at Chapel Hill,  received his Doctor of Pharmacy from the University of Cincinnati, and completed a residency at Cincinnati General Hospital. He is a graduate of the Owner/President Management Program at Harvard Business School.